Bristol Myers Squibb’s First Disclosures and New Data at ASH 2023 Highlight Company’s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology
November 2, 2023First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® (lisocabtagene maraleucel; liso-cel) in relapsed or refractory follicular lymphoma demonstrate its potential best-in-class and best-in-disease profile
Multiple new analyses of the Phase 3 KarMMa-3 study of Abecma® (idecabtagene vicleucel) in triple-class exposed relapsed and refractory multiple myeloma in earlier lines of therapy, including longer-term progression-free survival data and clinically meaningful improvements in patient-reported outcomes
New data from the Phase 3 COMMANDS study evaluating Reblozyl® (luspatercept-aamt), including results from the primary analysis and patient-reported outcomes, reinforce Reblozyl’s clinical benefit in erythropoiesis stimulating agent-naïve, myelodysplastic syndromes-related anemia
New results highlighting the enhanced immune-stimulating activity and combinability of targeted protein degradation agents in the treatment of relapsed or refractory multiple myeloma and non-Hodgkin’s lymphoma, including diffuse large B-cell lymphoma
Updated safety and efficacy data from the Phase 1 study of GPRC5D CAR T (BMS-986393/CC-95266) in patients with relapsed or refractory multiple myeloma, including in patients with prior BCMA-directed therapy
PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #ASH—Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research across its hematology and cell therapy portfolio and pipeline at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place in San Diego, California from December 9 to 12, 2023. Results from 73 data disclosures across company-sponsored studies will be featured, including 22 oral presentations, showcasing BMS’ commitment to delivering transformative medicines that help more patients living with blood disorders.
“At this year’s ASH meeting, we look forward to highlighting our continued commitment to unlocking the full promise of cell therapy and our differentiated research platforms, demonstrating the clinical and real-world value of our medicines through our scientific innovation,” said Samit Hirawat, M.D., executive vice president, chief medical officer, Global Drug Development, Bristol Myers Squibb. “New data from our diverse portfolio, spanning multiple platforms and combinations, reinforce our pursuit of the next wave of hematology advances across a spectrum of blood diseases with the highest unmet needs.”
Key data being presented by Bristol Myers Squibb and its partners at the 2023 ASH Annual Meeting and Exposition include:
Cell Therapy
- First disclosure of efficacy and safety data from the primary analysis of the Phase 2 TRANSCEND FL study of Breyanzi® (lisocabtagene maraleucel; liso-cel) for the treatment of patients with high-risk relapsed or refractory follicular lymphoma in the second-line setting. Patient-reported outcomes and health-related quality of life data from this study will also be presented.
- First disclosure of Center for International Blood and Marrow Transplant Research registry data showcasing safety and efficacy of Breyanzi in relapsed or refractory large B-cell lymphoma (LBCL) when used in the real world.
- Multiple analyses from the Phase 3 KarMMa-3 study evaluating Abecma® (idecabtagene vicleucel) in patients with triple-class exposed relapsed and refractory multiple myeloma, including final progression-free survival data, interim overall survival data, safety profile characterization and patient-reported outcomes from extended follow-up.
- Updated safety and efficacy results from the Phase 1 study of GPRC5D CAR T (BMS-986393/CC-95266) in patients with relapsed or refractory multiple myeloma, including in patients with prior BCMA-directed therapy.
Targeted Protein Degradation
- First results from the Phase 1/2 CC-92480 MM-002 study evaluating CELMoDTM agent mezigdomide with dexamethasone and daratumumab or elotuzumab in patients with relapsed or refractory multiple myeloma.
- Updated results from the dose-escalation and dose-expansion components of the Phase 1 CC-220-DLBCL-001 study, evaluating potential first-in-class CELMoD agent golcadomide in combination with R-CHOP in previously untreated diffuse LBCL.
- Translational data describing a potential mechanism of reversal of T-cell exhaustion by CELMoD agents, highlighting the potential for CELMoD agents to enhance T-cell redirecting therapies.
Additional Novel Treatment Modalities
- Multiple presentations from the Phase 3 COMMANDS study of Reblozyl® (luspatercept-aamt) in the treatment of anemia in patients with lower-risk myelodysplastic syndromes who are erythropoiesis stimulating agent-naïve, including primary analysis data, patient-reported outcomes and mutational analysis.
- Updated safety and efficacy data for potential best-in-class BET inhibitor BMS-986158 in combination with ruxolitinib or Inrebic® (fedratinib) in first- and second-line myelofibrosis.
- Updated safety and efficacy data for subcutaneous 2+1 T-cell engager alnuctamab in heavily pretreated multiple myeloma from the Phase 1 CC-93269-MM-001 study.
You can find additional information about BMS’ presence at the meeting on the ASH website.
Selected Bristol Myers Squibb studies at the 65th ASH Annual Meeting and Exposition include:
|
Abstract Title |
Author |
Presentation |
Session |
Session |
|
Beta Thalassemia |
||||
|
Improvement of Underlying Disease Pathophysiology of Ineffective Erythropoiesis in Non-Transfusion-Dependent (NTD) Patients with Beta-Thalassemia Receiving Luspatercept: Biomarker Analysis from the BEYOND Trial |
Manuel Ugidos Guerrero |
112. Thalassemia and Globin Gene Regulation: Poster III
|
Saturday, |
|
|
Real-World Characteristics, Treatment Utilization, and Transfusion Burden in Patients with β-Thalassemia Initiating Luspatercept: A US Cohort Study |
Sujit Sheth |
112. Thalassemia and Globin Gene Regulation: Poster II |
Sunday, |
|
|
Durable Symptom Improvement for Patients with Non-Transfusion Dependent Thalassemia Treated with Luspatercept: Patient-Reported Outcomes from the BEYOND Study |
Khaled Musallam |
112. Thalassemia and Globin Gene Regulation: Poster II |
Sunday, |
|
|
Efficacy and Safety of Luspatercept in Patients Enrolled in the BELIEVE Trial: Data from the Phase 3b Long-Term Rollover Study |
Maria Cappellini |
112. Thalassemia and Globin Gene Regulation: Poster III |
Monday, |
|
|
Luspatercept for the Treatment of Anemia in Non-Transfusion-Dependent β-Thalassemia: Final Safety and Efficacy Data from the BEYOND Trial |
Ali Taher |
112. Thalassemia and Globin Gene Regulation: Poster III |
Monday, |
|
|
Efficacy and Safety of Luspatercept in Patients with HbE/β‑Thalassemia from the BELIEVE Study: a Subgroup Analysis |
Kevin Kuo |
112. Thalassemia and Globin Gene Regulation: Poster III |
Monday, |
|
|
Leukemia |
||||
|
Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004 |
Tanya Siddiqi |
642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL |
Saturday, |
|
|
The Total Lifetime Cost of Treating Patients (Pts) with CLL in the United States (US) |
Farrukh Awan
|
902. Health Services and Quality Improvement – Lymphoid Malignancies: Poster I |
Saturday, |
|
|
Undetectable MRD Status in Patients with R/R CLL/SLL with Stable Disease After Lisocabtagene Maraleucel Treatment: Exploratory Analysis of the TRANSCEND CLL 004 Study |
Eniko Papp |
641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster II
|
Sunday, |
|
|
Lymphoma |
||||
|
Multicenter, Real-world Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US) |
Jennifer Crombie |
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for B Cell Lymphomas: Prospective Clinical Trials and Real World Data |
Saturday, |
|
|
Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study |
Alison Sehgal |
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for B Cell Lymphomas: Prospective Clinical Trials and Real World Data |
Saturday, |
|
|
Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study |
Lara Stepan |
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Translational Data and Prognostic Factors |
Saturday, |
|
|
Pharmacodynamic Biomarkers and CtDNA Support the Mechanism of Action and Clinical Efficacy of Golcadomide (CC-99282) Combined with R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma |
Mark Kaplan |
621. Lymphomas: Translational – Molecular and Genetic: Poster I
|
Saturday, |
|
|
Postinfusion Monitoring Health Care Resource Utilization and Costs by Site of Care Among Inpatients and Outpatients with Relapsed or Refractory Large B-Cell Lymphoma who Received Second-Line Treatment with Lisocabtagene Maraleucel in the TRANSFORM and PILOT Clinical Trials |
November McGarvey |
902. Health Services and Quality Improvement – Lymphoid Malignancies: Poster I
|
Saturday, |
|
|
Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) and Mosunetuzumab for the Treatment (Tx) of Third Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) |
Loretta Nastoupil |
902. Health Services and Quality Improvement – Lymphoid Malignancies: Poster I
|
Saturday, |
|
|
Patient-Reported Outcomes from the MCL Cohort of the Phase 1, Seamless Design TRANSCEND NHL 001 Study of Lisocabtagene Maraleucel in Patients with R/R B-Cell NHL |
Michael Wang |
905. Outcomes Research – Lymphoid Malignancies: Patient Reported Outcomes in Hematological Malignancies |
Sunday, |
|
|
TRANSCEND FL: Phase 2 Study Primary Analysis Results of Lisocabtagene Maraleucel in Patients with Second-Line High-risk Relapsed or Refractory Follicular Lymphoma |
Franck Morschhauser |
623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Immunotherapy |
Sunday, |
|
|
Patient-Reported Outcomes from the Phase 2 TRANSCEND FL Study of Lisocabtagene Maraleucel in Patients with Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma |
Guillaume Cartron |
905. Outcomes Research – Lymphoid Malignancies: Patient Reported Outcomes in Hematological Malignancies |
Sunday, |
|
|
Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001 Study |
Maria Lia Palomba |
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster II |
Sunday, |
|
|
Cytokine Release Syndrome and Neurological Event Management Resource Use and Costs Among Patients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Lisocabtagene Maraleucel Treatment in TRANSFORM and PILOT |
November McGarvey
|
902. Health Services and Quality Improvement – Lymphoid Malignancies: Poster II
|
Sunday, |
|
|
Golcadomide (GOLCA; CC-99282), a Novel CELMoD Agent, Plus R-CHOP in Patients (pts) with Previously Untreated Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy Results from Phase 1b Dose Expansion |
Marc Hoffmann |
626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III
|
Monday, |
|
|
Efficacy and Safety of Golcadomide, a Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, Combined with Rituximab in a Phase 1/2 Open-Label Study of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma |
Julio Chavez |
627. Aggressive Lymphomas: Clinical and Epidemiological: Poster III
|
Monday, |
|
|
Estimation of Postinfusion Resource Use and Total Costs of Care for Patients with R/R Follicular Lymphoma (FL) Receiving Lisocabtagene Maraleucel (liso-cel) in the TRANSCEND FL Study |
Ashley Saunders |
902. Health Services and Quality Improvement – Lymphoid Malignancies: Poster III |
Monday, |
|
|
Multiple Myeloma |
||||
|
Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2–4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial |
Michele Delforge |
652. Multiple Myeloma: Clinical and Epidemiological: T Cell Redirecting Therapy Outcomes and Associated Complications |
Saturday, |
|
|
BMS-986393 (CC-95266), a G protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study |
Susan Bal |
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Expanding Disease Targets for CAR-T Cell Therapies |
Saturday, |
|
|
Mezigdomide reverses T-Cell exhaustion through degradation of Aiolos/Ikaros and Reinvigoration of cytokine production pathways |
Hsiling Chiu |
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterization of the MM and the Tumor Microenvironment |
Saturday, |
|
|
Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First‑in‑Human Clinical Study |
Noffar Bar |
653. Multiple Myeloma: Prospective Therapeutic Trials: Poster I
|
Saturday, |
|
|
Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (MM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up |
Madhav Dhodapkar |
704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster I |
Saturday, |
|
|
Patient (pt) Experiences of Receiving Idecabtagene Vicleucel (Ide-Cel, bb2121) Versus Standard (Std) Regimens for the Treatment (Tx) of Relapsed/Refractory Multiple Myeloma (RRMM) in the Randomized, Controlled KarMMa-3 Clinical Trial: Analysis of Longitudinal Qualitative Interviews |
Paula Rodriguez Otero |
905. Outcomes Research – Lymphoid Malignancies: Poster I
|
Saturday, |
|
|
Preclinical and Translational Biomarker Analyses to Inform Clinical Development of Mezigdomide (CC-92480) in Combination with Dexamethasone and Daratumumab in Multiple Myeloma |
Tracy Chow |
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II |
Sunday, |
|
|
Healthcare Resource Utilization and Economic Burden of Cytokine Release Syndrome and Neurotoxicity in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Receiving Idecabtagene Vicleucel in Earlier-Line Settings in the KarMMa-3 Clinical Trial |
Sikander Ailawadhi |
905. Outcomes Research—Lymphoid Malignancies: Poster II
|
Sunday, |
|
|
Clinical Outcomes in Real-World Patients (RW) with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM): A Retrospective Study using Electronic Health Records from Flatiron Health and COTA Vantage Databases |
Hans C Lee |
905. Outcomes Research—Lymphoid Malignancies: Poster II
|
Sunday, |
|
|
Treatment Patterns and Outcomes for Patients with Newly Diagnosed Multiple Myeloma Post-Stem Cell Transplantation Who Received Lenalidomide As First Line Maintenance Therapy (PREAMBLE) |
Ravi Vij |
905. Outcomes Research—Lymphoid Malignancies: Poster II
|
Sunday, |
|
|
Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Triple-Class-Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Who Received at Least 3 Lines of Prior Antimyeloma Regimens in the KarMMa-3 Phase 3 Randomized Controlled Trial |
Michele Delforge |
652. Multiple Myeloma: Clinical and Epidemiological: Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma |
Monday, |
|
|
A Pro-Inflammatory State and Peak Cytokines Are Associated with Toxicity and Early Responses in Real-World Multiple Myeloma Patients Treated with Idecabtagene Vicleucel |
Doris Hansen |
652. Multiple Myeloma: Clinical and Epidemiological: Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma |
Monday, |
|
|
Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients (pts) with Triple-Class Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3 |
Paula Rodriguez-Otero |
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas: Clinical Trial and Real World Evidence |
Monday, |
|
|
Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial |
Paul Richardson |
653. Multiple Myeloma: Prospective Therapeutic Trials: Relapsed and Refractory Myeloma |
Monday, |
|
|
RRMM and Post-BCMA Treated Subjects from the CC-220-MM-001 Study Show Increased Genomic Aberrations Associated with High-Risk and Significant Dysfunction in CD4+ T-Cell Compartment Compared to NDMM Subjects |
Michael Amatangelo |
651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III
|
Monday, |
|
|
Idecabtagene Vicleucel (Ide-cel) versus Standard (std) Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Patients (pts) From KarMMa-3 |
Rachid Baz |
705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III |
Monday, |
|
|
Facility-Related Healthcare Resource Utilization (HCRU) for Patients Treated with Idecabtagene Vicleucel (Ide-Cel, bb2121) in a Real-World (RW) Setting: A Single-Center Experience |
Lauren Peres |
902. Health Services and Quality Improvement – Lymphoid Malignancies: Poster III |
Monday, |
|
|
Myelodysplastic Syndromes |
||||
|
Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial |
Guillermo Garcia-Manero |
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Treatment Options and Decision Making in Low Risk MDS |
Saturday, |
|
|
GDF11/SMAD Regulated Splicing of GATA1 Is Associated with Response to Luspatercept in Lower-Risk Myelodysplastic Syndromes (LR MDS) |
Srinivas Aluri |
636. Myelodysplastic Syndromes – Basic and Translational: Molecular Drivers and Therapeutic Implications |
Saturday, |
|
|
Luspatercept Modulates Inflammation in the Bone Marrow, Restores Effective Erythropoiesis/Hematopoiesis, and Provides Sustained Clinical Benefit versus Epoetin Alfa (EA): Biomarker Analysis from the Phase 3 COMMANDS Study |
Sheida Hayati |
636. Myelodysplastic Syndromes – Basic and Translational: Poster I
|
Saturday, |
|
|
Clonal Hematopoiesis-Related Mutations Are Associated with Favorable Clinical Benefit Following Luspatercept Treatment in Patients with Lower-Risk Myelodysplastic Syndromes: A Subgroup Analysis from the Phase 3 COMMANDS Trial |
Maroof Hasan |
636. Myelodysplastic Syndromes—Basic and Translational: Poster II
|
Sunday, |
|
|
Real-World Retrospective Study of Non-Transfusion Dependent Patients with Myelodysplastic Syndromes in a Large Healthcare Claims Database |
Leslie Andritsos |
906. Outcomes Research—Myeloid Malignancies: Poster II |
Sunday, |
|
|
Long-Term Evaluation of Luspatercept in Erythropoiesis Stimulating Agent (ESA)-Intolerant/Refractory Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Phase 3 MEDALIST Study |
Valeria Santini |
906. Outcomes Research – Myeloid Malignancies: Symptom Burden and Supportive Therapies |
Monday, |
|
|
Real-World Impact of Luspatercept on Patients with Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions and with Prior Exposure to Erythropoietin Stimulating Agents in a Large Healthcare Claims Database |
Kashyap Patel |
906. Outcomes Research – Myeloid Malignancies: Symptom Burden and Supportive Therapies |
Monday, |
|
|
Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naïve, Transfusion-Dependent (TD), Low-Risk Myelodysplastic Syndromes (MDS): Results from the Phase 3 COMMANDS Study |
Esther Oliva |
637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster III
|
Monday, |
|
|
Impact of Genomic Landscape and Mutational Burden on Primary Endpoint Responses in the COMMANDS Study |
Rami Komrokji |
636. Myelodysplastic Syndromes—Basic and Translational: Poster III |
Monday, |
|
|
Myelofibrosis |
||||
|
Patient Characteristics, Treatment Patterns, and Health Outcomes in a Real-World Population of Patients with Myelofibrosis Treated with Fedratinib |
Francesco Passamonti
|
906. Outcomes Research – Myeloid Malignancies: Poster I |
Saturday, |
|
|
BMS-986158, a Potent BET Inhibitor, in Combination with Ruxolitinib or Fedratinib in Patients (pts) with Intermediate- or High-risk Myelofibrosis (MF): Updated Results from a Phase 1/2 Study |
David Lavie |
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Charting the Future of MPN Therapies |
Sunday, |
|
|
Modulation of Biomarkers by BET Inhibitor, BMS-986158, Including JAK2 Variant Allele Frequency (VAF), Bone Marrow (BM) Fibrosis, and Reversal of Abnormal Cytokine Production in Intermediate- or High-Risk Myelofibrosis (MF) |
Si Tuen Lee-Hoeflich |
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II |
Sunday, |
|
|
Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study |
Claire Harrison |
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II |
Sunday, |
|
|
Fedratinib Treatment Reduces the Inflammatory Cytokine Profile and Decreases Exhausted T Cells Correlating with Clinical Response in Patients with Myelofibrosis: Biomarker Analysis from the Phase 3 FREEDOM2 Trial |
Danny Jeyaraju |
631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III |
Monday, |
|
|
Clinical Parameters, Anemia, and Spleen Response in Patients with MF-Related Anemia Treated with Luspatercept: Efficacy Sub-Analysis from the ACE-536-MF-001 Study |
Aaron Gerds |
634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III |
Monday, |
|
Contacts
Bristol Myers Squibb:
Media Inquiries:
[email protected]
Investors:
[email protected]